BACKGROUND: Skin cancers are common, and there has recently been a dramatic increase in their incidence, particularly in the occurrence of melanoma. Furthermore, relapse after curative surgical treatment of melanoma remains a significant clinical challenge and accounts for most of the mortality of this disease. OBJECTIVE: The aim of this study was to determine whether IMMUNEPOTENT CRP affects B16F10 melanoma cells and tumors growth and vascular endothelial growth factor (VEGF) production in vivo and in vitro. METHODS: B16F10 cells and B16F10-inoculated mice were treated with different concentrations of IMMUNEPOTENT CRP. Outcomes were then evaluated using MTT, TUNEL, Caspase-3, senescence, ELISA and colorimetric assays. Parameters related to survival and tumor weight were also assessed. RESULTS: IMMUNEPOTENT CRP decreased the viability of B16F10 cells by increasing apoptosis of the treated cells, and VEGF production was decreased both in vitro and in vivo. Furthermore, treatment prevented metastasis, delayed the appearance of tumors, decreased tumor weight and improved the survival of tumor-bearing mice. DISCUSSION: These observations suggest that IMMUNEPOTENT CRP can be used to suppress growth and metastasis by using targeting proteins such as VEGF.
BACKGROUND:Skin cancers are common, and there has recently been a dramatic increase in their incidence, particularly in the occurrence of melanoma. Furthermore, relapse after curative surgical treatment of melanoma remains a significant clinical challenge and accounts for most of the mortality of this disease. OBJECTIVE: The aim of this study was to determine whether IMMUNEPOTENT CRP affects B16F10 melanoma cells and tumors growth and vascular endothelial growth factor (VEGF) production in vivo and in vitro. METHODS: B16F10 cells and B16F10-inoculated mice were treated with different concentrations of IMMUNEPOTENT CRP. Outcomes were then evaluated using MTT, TUNEL, Caspase-3, senescence, ELISA and colorimetric assays. Parameters related to survival and tumor weight were also assessed. RESULTS: IMMUNEPOTENT CRP decreased the viability of B16F10 cells by increasing apoptosis of the treated cells, and VEGF production was decreased both in vitro and in vivo. Furthermore, treatment prevented metastasis, delayed the appearance of tumors, decreased tumor weight and improved the survival of tumor-bearing mice. DISCUSSION: These observations suggest that IMMUNEPOTENT CRP can be used to suppress growth and metastasis by using targeting proteins such as VEGF.
Authors: Crystel A Sierra-Rivera; Moisés A Franco-Molina; Edgar Mendoza-Gamboa; Pablo Zapata-Benavides; Jesús Santaolalla-Tapia; Erika E Coronado-Cerda; Reyes S Tamez-Guerra; Cristina Rodríguez-Padilla Journal: Oncol Lett Date: 2016-10-18 Impact factor: 2.967
Authors: Maria Del Carmen Rodríguez-Salazar; Moises Armides Franco-Molina; Edgar Mendoza-Gamboa; Ana Carolina Martínez-Torres; Pablo Zapata-Benavides; Jose Sullivan López-González; Erika Evangelina Coronado-Cerda; Juan Manuel Alcocer-González; Reyes Silvestre Tamez-Guerra; Cristina Rodríguez-Padilla Journal: Oncol Lett Date: 2017-05-18 Impact factor: 2.967
Authors: Ana Carolina Martínez-Torres; Alejandra Reyes-Ruiz; Kenny Misael Calvillo-Rodriguez; Karla Maria Alvarez-Valadez; Ashanti C Uscanga-Palomeque; Reyes S Tamez-Guerra; Cristina Rodríguez-Padilla Journal: BMC Cancer Date: 2020-07-13 Impact factor: 4.430
Authors: Luis Gomez-Morales; Alan B Martinez-Loria; Ana Carolina Martinez-Torres; Ashanti Concepcion Uscanga-Palomeque; Jose Manuel Vazquez-Guillen; Cristina Rodriguez-Padilla Journal: PeerJ Date: 2019-09-27 Impact factor: 2.984